[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"short-coupled-ventricular-fibrillation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:short-coupled-ventricular-fibrillation":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100588589",false,"NCT06943365","Role of Anti-TREK-1 Autoantibodies in SCVF","Circulating Anti-TREK-1 Autoantibodies as Diagnostic and Prognostic Biomarkers in Short-Coupled Ventricular Fibrillation","TRACK-VF","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of SCVF as per current criteria\n* Willingness to provide written informed consent\n\nExclusion Criteria:\n\n\\- SCVF patients \\\u003C age 18","ALL","18 Years",{"count":19,"type":20},300,"ESTIMATED","24 Months","OBSERVATIONAL","Short-coupled ventricular fibrillation (SCVF) is a lethal, primary electrical disorder and an important cause of unexplained cardiac arrest.1 Recent work from our group suggests that a substantial proportion of SCVF cases is associated to circulating autoantibodies targeting TREK-1, a cardiac potassium channel, resulting in an abnormal gain-of-function which is the prerequisite for the SCVF phenotype.2 This proposal is a translational multicenter study to validate anti-TREK-1 autoantibodies as a diagnostic and prognostic biomarker in a large, diversified cohort of SCVF patients (Figure 1). Functional, cellular experiments in patient-derived hiPSC cardiomyocytes and Purkinje cells will be performed to explore the cell type-specific role of TREK-1 in arrhythmogenesis, while single-nuclear RNA sequencing (snRNA-seq) will allow us to establish the transcriptomic profile (Figure 1). These results will identify the cellular substrate for SCVF.",[25,26],"Short-coupled Ventricular Fibrillation","Idiopathic Ventricular Fibrillation",[28,29,30],"SCVF","anti-TREK-1 antibodies","IVF","RECRUITING","2026-06-15",{"date":34,"type":35},"2026-06-16","ACTUAL",{"date":37,"type":35},"2025-05-01",{"date":39,"type":20},"2028-12-31",{"name":41,"class":42},"Institut universitaire de cardiologie et de pneumologie de Québec, University Laval","OTHER",5,""]